Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
T-PRED · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| T-Pred | EXPERIMENTAL | Tobramycin prednisolone acetate combination |
| Pred Forte | ACTIVE_COMPARATOR | Prednisolone acetate |
| Name | Type | Description |
|---|---|---|
| T-Pred | DRUG | sterile ophthalmic solution |
| Pred Forte | DRUG | sterile ophthalmic solution |
Inclusion Criteria: * 18 years of age or older Exclusion Criteria: * No active or adverse disease
T-PRED is an investigational small molecule being developed for use in cataract surgery. It is a corticosteroid designed to manage inflammation following cataract procedures. The drug is currently in clinical development and has not been approved by the FDA.
T-PRED is being developed by Bausch + Lomb Corporation, which trades under the ticker BLCO. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients undergoing cataract surgery.
T-PRED is in Phase 3 clinical development. It has completed two trials, including a Phase 2 study and a Phase 3 study, both of which were conducted in the United States. The drug remains investigational and is not yet approved.
T-PRED has completed two clinical trials. The first, NCT00699803, was a Phase 2 study comparing T-PRED to Pred Forte in 64 cataract patients. The second, NCT00854061, was a Phase 3 study comparing T-PRED to Pred Forte in 172 cataract patients. Both trials were randomized, double-blind, and active-controlled.
No, T-PRED is not the same as Pred Forte. T-PRED is an investigational drug being developed by Bausch + Lomb, while Pred Forte is a commercially available corticosteroid used as an active comparator in clinical trials. The trials directly compared the two treatments for cataract-related inflammation.